United Therapeutics Corporation $UTHR Stake Boosted by Danske Bank A S

Key Points

• Danske Bank A/S increased its stake in United Therapeutics by 21.8% in Q4 to 19,473 shares, worth about $9.49 million, and institutional investors now own roughly 94.08% of the stock.
• Insider selling has been sizable: CFO James Edgemond sold 10,000 shares and COO Michael Benkowitz sold 22,500 shares, and insiders have sold 456,155 shares (≈$248.66M) over the last 90 days, leaving insiders with about 10.30% ownership.
• Fundamentals and analyst outlook: United Therapeutics topped EPS estimates ($7.70 vs. $6.78) while slightly missing revenue, trades with a market cap near $25.5B, and analysts have raised targets to an average of $601.50 with a "Moderate Buy" consensus.

Danske Bank A S grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 21.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,473 shares of the biotechnology company's stock after purchasing an additional 3,484 shares during the quarter. Danske Bank A S's holdings in United Therapeutics were worth $9,488,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Clearstead Advisors LLC grew its position in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after acquiring an additional 23 shares during the last quarter. Bessemer Group Inc. grew its position in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock worth $472,000 after acquiring an additional 28 shares during the last quarter. Archer Investment Corp grew its position in shares of United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company's stock worth $149,000 after acquiring an additional 31 shares during the last quarter. Signaturefd LLC grew its position in shares of United Therapeutics by 4.1% during the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company's stock worth $437,000 after acquiring an additional 35 shares during the last quarter. Finally, WealthCollab LLC grew its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of the firm's stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 456,155 shares of company stock valued at $248,660,944. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $581.22 on Tuesday. The stock has a fifty day moving average price of $543.83 and a two-hundred day moving average price of $498.27. The firm has a market cap of $25.47 billion, a P/E ratio of 20.83, a PEG ratio of 1.62 and a beta of 0.60. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm's quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the company posted $6.19 EPS. On average, research analysts predict that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. HC Wainwright increased their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a report on Tuesday, March 31st. Bank of America increased their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a report on Tuesday, March 31st. Royal Bank Of Canada increased their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. UBS Group increased their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Finally, Wells Fargo & Company increased their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $601.50.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.